Speaker Profile
Ph.D., Dual PhD., CEO and CSO, Phinomics
Biography
Massa Shoura is the CEO and CSO of Phinomics, an innovative companytransforming precision medicine by unlocking the potential of circular DNAand integrating genomics with advanced AI. With dual PhDs in MolecularBiology and Biomedical Engineering, Massa has over a decade of expertise inDNA topology, biophysics, and genomics. During her postdoctoral fellowshipat Stanford University in Nobel Laureate Dr. Andrew Fires lab, shedeveloped groundbreaking tools for isolating and characterizing circularDNA, earning prestigious fellowships, including the Arnold O. BeckmanFellowship, and securing two granted patents. As a Forbeck Scholar, sheadvanced cancer genomics by uncovering the role of oncogenic circular DNAamplification. She also spearheaded the sequencing and publication ofPfizer and Moderna COVID-19 vaccine mRNAs, showcasing her commitment toglobal health. At Phinomics, Massa leads the development of first-in-classprecision oncology solutions through the Circulome Atlas, a transformativeplatform providing unparalleled insights into cancer etiology, progression,and therapeutic resistance.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, Cytoreason
Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, Biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Sanoj Punnen, University of Miami
• Shivanni Kummar, OHSU
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug?
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
